All News

Pharmacogenomic information can be used to more selectively choose medications and doses that are more appropriate for each individual.

This guide discusses the integration of continuous glucose monitoring (CGM) technology into clinical practice, emphasizing the role of pharmacists in selecting and optimizing CGM devices for patients.

The early phase clinical trial, which ended prematurely in 2013 due to funding challenges, further illustrates disparities in health equity in clinical research.

This initiative aims to raise worldwide awareness of the disease while trying to strengthen the connection between members of the multiple myeloma community.

If clinical trials continue to show that psychedelics offer safe and long-lasting results, then psychedelic-assisted therapy could flourish as a treatment in the mental health space.

Secukinumab affects levels of inflammatory biomarkers, and monitoring levels can help investigators understand how patients are responding to treatment.

GBS can cause transcriptional adaptations, which may increase risk of poor neonate outcomes.

The IVIG therapies were previously approved for 4-week room temperature storage conditions of 25º Celsius during the first 24 months of shelf life.

Contract pharmacies should work to stay in a perpetual state of audit readiness

CGM enhances diabetes management in pregnancy, improving outcomes.

In addition, the length of hospital admissions were greater in patients with hidradenitis suppurativa-associated cutaneous squamous cell carcinoma compared to other admissions.

Semaglutide (Wegovy; Novo Nordisk) reduces the risk of cardiovascular death, heart attack, and stroke in adults with cardiovascular disease and either obesity or overweight when combined with the standard-of-care.

In the State of the Union Address, President Biden said he wants to expand the $2,000 out-of-pocket cap beyond seniors and allow Medicare to negotiate more costly drugs.

The biosimilarity was evident between SB17 (Samsung Bioepis), ustekinumab (Stelara; Janssen Immunology), and those switching from ustekinumab to SB17.

The FDA is convening a committee to discuss phase 3 data after the planned action date, which delays drug availability to patients.

Despite the belantamab mafodotin regimen improving overall survival in patients with relapsed or refractory multiple myeloma, the trial is ongoing to confirm the presented results.

The vice president and chief pharmacy officer at City of Hope explains how she serves as a mentor for women within health care, the importance of networking, and staying educated.

These employees build operational workflows, predictive analytical tools, implement and refine clinical decision support technologies, increase efficiency, and more.

The pharmacy supply chain and reimbursement marketplace are broken, manufacturers are throwing up their hands and getting into the vertical integration scrum

Cardinal Health released its 2024 biosimilars report, including research and in-depth analyses on legislative development, payer landscapes, and new treatments in the pipeline.

The vice president and chief pharmacy officer of City of Hope discusses obstacles women face in health care and how diversity, equity, and inclusion can be promoted within the space.

Patients with urothelial carcinoma who were treated with the nivolumab-based regimen had better OS and PFS compared with those who received cisplatin with gemcitabine alone.

The application was previously granted fast track designation and orphan drug designation.

Individuals with persistent asthma and at least 1 complex comorbidity were more likely to use telemedicine, the results of the study showed.

Teplizumab is indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and pediatric patients 8 years of age and older with stage 2 T1D.

Promising data have emerged suggesting a significant weight loss benefit for patients using GLP-1 agonists and GLP-1/GIP dual agonists.

The study is a companion study to the ROCKstar study, which investigated the drug in individuals with cGVHD who received 2 to 5 prior lines of therapy.